Gracell Biotechnologies Inc.
GRCL
Cena:
Valuace
70
Růst
0
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
GRACELL BIOTECHNOLOGIES ACQUISITION COMPLETED
22-02-2024
SAN DIEGO AND SUZHOU, CHINA AND SHANGHAI, CHINA, FEB. 22, 2024 (GLOBE NEWSWIRE) -- GRACELL BIOTECHNO...
Více zde
GRACELL BIOTECHNOLOGIES ANNOUNCES SHAREHOLDERS' APPROVAL OF MERGER AGREEMENT
20-02-2024
SAN DIEGO AND SUZHOU, CHINA AND SHANGHAI, CHINA, FEB. 20, 2024 (GLOBE NEWSWIRE) -- GRACELL BIOTECHNO...
Více zde
GRACELL BIOTECHNOLOGIES ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR PHASE 1 CLINICAL TRIAL OF FASTCAR-T GC012F AS EARLY-LINE TREATMENT OF MULTIPLE MYELOMA
29-01-2024
FURTHER EXPANDS CLINICAL DEVELOPMENT OF FASTCAR-T GC012F IN MULTIPLE MYELOMA AMID ONGOING U.S. TRIAL...
Více zde
GRACELL BIOTECHNOLOGIES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF GRACELL BIOTECHNOLOGIES INC. - GRCL
31-12-2023
NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND TH...
Více zde
GRCL STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF GRACELL BIOTECHNOLOGIES INC. IS FAIR TO SHAREHOLDERS
26-12-2023
NEW YORK--(BUSINESS WIRE)--HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING WHETHER T...
Více zde
ASTRAZENECA TO ACQUIRE GRACELL, FURTHERING CELL THERAPY AMBITION ACROSS ONCOLOGY AND AUTOIMMUNE DISEASES
26-12-2023
WILMINGTON, DEL.--(BUSINESS WIRE)--ASTRAZENECA HAS ENTERED INTO A DEFINITIVE AGREEMENT TO ACQUIRE GR...
Více zde
GRACELL BIOTECHNOLOGIES TO BE ACQUIRED BY ASTRAZENECA, FURTHERING CELL THERAPY AMBITION ACROSS ONCOLOGY AND AUTOIMMUNE DISEASES
26-12-2023
PROPOSED ACQUISITION WILL ENRICH THE ASTRAZENECA CELL THERAPY PIPELINE WITH CLINICAL-STAGE AUTOLOGOU...
Více zde
GRACELL BIOTECHNOLOGIES ANNOUNCES CHINA NMPA CLEARANCE FOR IND APPLICATION FOR PHASE 1/2 CLINICAL TRIAL OF FASTCAR-T GC012F FOR THE TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
21-12-2023
EXPANDS CLINICAL DEVELOPMENT OF GC012F IN RSLE FOLLOWING FDA IND CLEARANCE FOR PHASE 1/2 TRIAL IN TH...
Více zde
GRACELL BIOTECHNOLOGIES PRESENTS UPDATED CLINICAL DATA FROM FASTCAR-T GC012F DEMONSTRATING DEEP AND DURABLE RESPONSES IN NEWLY DIAGNOSED MULTIPLE MYELOMA AT ASH 2023
11-12-2023
MINIMAL RESIDUAL DISEASE NEGATIVITY (MRD-) OBSERVED IN ALL TREATED PATIENTS IN THE ONGOING STUDY, WI...
Více zde
GRACELL BIOTECHNOLOGIES ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR PHASE 1/2 CLINICAL TRIAL OF FASTCAR-T GC012F FOR THE TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
27-11-2023
GRACELL IS PIONEERING USE OF A CD19/BCMA DUAL-TARGETED CAR-T CELL THERAPY IN REFRACTORY SYSTEMIC LUP...
Více zde
GRACELL BIOTECHNOLOGIES TO PARTICIPATE IN INAUGURAL CELL THERAPY FOR AUTOIMMUNE DISEASE SUMMIT
16-11-2023
PRESENTATION TO FOCUS ON APPLICATION OF NEXT-GENERATION CAR-T CELL THERAPY TECHNOLOGIES FOR TREATMEN...
Více zde
GRACELL BIOTECHNOLOGIES REPORTS THIRD QUARTER 2023 UNAUDITED FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
13-11-2023
SAN DIEGO, CALIF. AND SUZHOU AND SHANGHAI, CHINA, NOV. 13, 2023 (GLOBE NEWSWIRE) -- GRACELL BIOTECHN...
Více zde
GRACELL BIOTECHNOLOGIES WINS OVERALL IMMUNOLOGY SOLUTION OF THE YEAR BY BIOTECH BREAKTHROUGH AWARDS PROGRAM
08-11-2023
THIRD ANNUAL BIOTECH BREAKTHROUGH AWARD RECOGNIZES EXCELLENCE IN LIFE SCIENCE AND BIOTECHNOLOGY SOLU...
Více zde
GRACELL BIOTECHNOLOGIES TO PRESENT UPDATED RESULTS FROM BCMA/CD19 DUAL-TARGETING FASTCAR-T GC012F IN NEWLY DIAGNOSED MULTIPLE MYELOMA AT THE 65ᵗʰ AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING & EXPOSITION
02-11-2023
ORAL PRESENTATION OF THE UPDATED RESULTS FROM ONGOING PHASE 1 INVESTIGATOR-INITIATED STUDY OF GC012F...
Více zde
GRACELL BIOTECHNOLOGIES TO PARTICIPATE IN FOUR UPCOMING INVESTOR CONFERENCES
01-11-2023
SAN DIEGO AND SUZHOU, CHINA AND SHANGHAI, CHINA, NOV. 01, 2023 (GLOBE NEWSWIRE) -- GRACELL BIOTEC...
Více zde
GRACELL BIOTECHNOLOGIES TO PRESENT DATA HIGHLIGHTING PRECLINICAL EFFICACY OF SMART CART™ AGAINST SOLID TUMORS AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 38TH ANNUAL MEETING
31-10-2023
NOVEL, PROPRIETARY TECHNOLOGY DESIGNED TO STRENGTHEN THE FUNCTIONALITY OF CAR-T CELLS AGAINST SOLID ...
Více zde
GRACELL BIOTECHNOLOGIES TO REPORT THIRD QUARTER 2023 FINANCIALS ON MONDAY, NOVEMBER 13, 2023
30-10-2023
SAN DIEGO AND SUZHOU, CHINA AND SHANGHAI, CHINA, OCT. 30, 2023 (GLOBE NEWSWIRE) -- GRACELL BIOTECHNO...
Více zde
GRACELL BIOTECHNOLOGIES REPORTS UPDATED CLINICAL DATA FOR FASTCAR-T GC012F FOR HIGH-RISK, NEWLY DIAGNOSED MULTIPLE MYELOMA, DEMONSTRATING 100% STRINGENT COMPLETE RESPONSE RATE
27-09-2023
SAN DIEGO AND SUZHOU, CHINA AND SHANGHAI, CHINA, SEPT. 27, 2023 (GLOBE NEWSWIRE) -- GRACELL BIOTECHN...
Více zde
GRACELL BIOTECHNOLOGIES DOSES FIRST PATIENT IN PHASE 1B/2 CLINICAL TRIAL IN U.S. EVALUATING GC012F FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA
26-09-2023
SAN DIEGO AND SUZHOU, CHINA AND SHANGHAI, CHINA, SEPT. 26, 2023 (GLOBE NEWSWIRE) -- GRACELL BIOTECHN...
Více zde
GRACELL BIOTECHNOLOGIES' CEO DR. WILLIAM CAO NAMED TO PRESTIGIOUS PHARMAVOICE 100, HONORING MOST INSPIRING LIFE SCIENCE LEADERS
19-09-2023
SAN DIEGO AND SUZHOU, CHINA AND SHANGHAI, CHINA, SEPT. 19, 2023 (GLOBE NEWSWIRE) -- GRACELL BIOTECHN...
Více zde
GRACELL BIOTECHNOLOGIES TO PARTICIPATE IN THREE UPCOMING INVESTOR CONFERENCES
14-09-2023
SAN DIEGO AND SUZHOU, CHINA AND SHANGHAI, CHINA, SEPT. 14, 2023 (GLOBE NEWSWIRE) -- GRACELL BIOTECH...
Více zde
GRACELL BIOTECHNOLOGIES TO PRESENT UPDATED CLINICAL DATA ON BCMA/CD19 DUAL-TARGETING FASTCAR-T GC012F IN NEWLY DIAGNOSED MULTIPLE MYELOMA AT THE 2023 INTERNATIONAL MYELOMA SOCIETY ANNUAL MEETING
06-09-2023
SAN DIEGO, CALIF., AND SUZHOU AND SHANGHAI, CHINA , SEPT....
Více zde
GRACELL BIOTECHNOLOGIES TO PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES
24-08-2023
SAN DIEGO AND SUZHOU, CHINA AND SHANGHAI, CHINA, AUG. 24, 2023 (GLOBE NEWSWIRE) -- GRACELL BIOTECHNO...
Více zde
GRACELL BIOTECHNOLOGIES REPORTS SECOND QUARTER 2023 UNAUDITED FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
14-08-2023
SAN DIEGO AND SUZHOU, CHINA AND SHANGHAI, CHINA, AUG. 14, 2023 (GLOBE NEWSWIRE) -- GRACELL BIOTECHNO...
Více zde
GRACELL BIOTECHNOLOGIES ANNOUNCES UP TO $150 MILLION PRIVATE PLACEMENT FINANCING JOINED BY A SYNDICATE OF PREMIER HEALTHCARE INVESTORS
07-08-2023
OVERSUBSCRIBED TRANSACTION LED BY VIVO CAPITAL AND JOINED BY LEADING HEALTHCARE INVESTORS INCLUDING...
Více zde
GRACELL BIOTECHNOLOGIES TO REPORT SECOND QUARTER 2023 FINANCIALS ON MONDAY, AUGUST 14, 2023
31-07-2023
SAN DIEGO AND SUZHOU, CHINA AND SHANGHAI, CHINA, JULY 31, 2023 (GLOBE NEWSWIRE) -- GRACELL BIOTECHNO...
Více zde
GRACELL BIOTECHNOLOGIES TO PARTICIPATE IN BTIG VIRTUAL BIOTECHNOLOGY CONFERENCE
31-07-2023
SAN DIEGO AND SUZHOU AND SHANGHAI, CHINA, JULY 31, 2023 (GLOBE NEWSWIRE) -- GRACELL BIOTECHNOLOGIES ...
Více zde
GRACELL BIOTECHNOLOGIES TO PARTICIPATE IN TRUIST SECURITIES CELL THERAPY SYMPOSIUM
20-06-2023
SAN DIEGO AND SUZHOU AND SHANGHAI, CHINA, JUNE 20, 2023 (GLOBE NEWSWIRE) -- GRACELL BIOTECHNOLOGIES ...
Více zde
GRACELL BIOTECHNOLOGIES PRESENTS LONGER-TERM RESULTS FOR FASTCAR-T GC012F IN B-CELL NON-HODGKIN'S LYMPHOMA AT EHA2023, HIGHLIGHTING 100% OVERALL RESPONSE RATE
10-06-2023
DATA ON CD19/BCMA DUAL-TARGETING FASTCAR-T GC012F SHOWED 100% OVERALL RESPONSE RATE (ORR) AND 66.7% ...
Více zde
GRACELL BIOTECHNOLOGIES PRESENTS UPDATED DATA OF DEEP AND DURABLE RESPONSES FOR FASTCAR-T GC012F IN RELAPSED/REFRACTORY MULTIPLE MYELOMA AT 2023 ASCO ANNUAL MEETING
03-06-2023
DATA ON BCMA/CD19 DUAL-TARGETING FASTCAR-T GC012F SHOWED 100% MINIMAL RESIDUAL DISEASE (MRD) NEGATIV...
Více zde
Dokumenty nejsou k dispozici
